$RLYB
Rallybio Corp

2022 Q3 Form 10-Q Financial Statement

#000095017022015571 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.750M $7.477M $6.670M
YoY Change 34.44% 101.43% 76.13%
% of Gross Profit
Research & Development $12.11M $10.14M $7.648M
YoY Change 144.15% 48.69% -15.37%
% of Gross Profit
Depreciation & Amortization $42.00K $44.00K $42.00K
YoY Change 61.54% 76.0% -321.05%
% of Gross Profit
Operating Expenses $18.86M $17.62M $14.32M
YoY Change 88.96% 67.28% 11.65%
Operating Profit -$18.86M -$17.62M -$14.32M
YoY Change 88.96% 67.28% 11.65%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $623.0K $370.0K $210.0K
YoY Change 432.48% -386.82% 577.42%
Pretax Income -$18.24M -$17.25M -$14.11M
YoY Change 84.88% 61.79% 10.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.37M -$17.58M -$14.50M
YoY Change 80.17% 58.02% 9.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60 -$0.57 -$0.48
Diluted Earnings Per Share -$0.60 -$0.57 -$478.2K
COMMON SHARES
Basic Shares Outstanding 32.13M 30.59M 32.13M
Diluted Shares Outstanding 30.78M 30.59M 30.32M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $132.4M $147.4M $161.4M
YoY Change -29.18% 30.73% 26.36%
Cash & Equivalents $51.71M $60.75M $81.43M
Short-Term Investments $80.71M $86.62M $79.98M
Other Short-Term Assets $1.176M $6.931M $6.373M
YoY Change -78.28% 21.55% 559.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $142.4M $154.3M $167.8M
YoY Change -25.97% 30.29% 30.36%
LONG-TERM ASSETS
Property, Plant & Equipment $424.0K $468.0K $499.0K
YoY Change -4.72% 52.94% 59.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $244.0K $227.0K $415.0K
YoY Change -76.26% -83.31% 26.52%
Other Assets
YoY Change
Total Long-Term Assets $1.237M $1.308M $1.571M
YoY Change -16.02% -21.49% 145.47%
TOTAL ASSETS
Total Short-Term Assets $142.4M $154.3M $167.8M
Total Long-Term Assets $1.237M $1.308M $1.571M
Total Assets $143.7M $155.6M $169.4M
YoY Change -25.89% 29.57% 30.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $828.0K $633.0K $1.057M
YoY Change -68.14% -75.86% -64.87%
Accrued Expenses $10.30M $6.495M $4.595M
YoY Change 117.11% 35.71% 49.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.30M $7.278M $5.800M
YoY Change 53.8% -1.75% -4.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $428.0K $478.0K $517.0K
YoY Change 1122.86% 1670.37% 2485.0%
Total Long-Term Liabilities $428.0K $478.0K $517.0K
YoY Change 1122.86% 1670.37% 2485.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.30M $7.278M $5.800M
Total Long-Term Liabilities $428.0K $478.0K $517.0K
Total Liabilities $11.72M $7.756M $6.317M
YoY Change 58.87% 4.32% 3.57%
SHAREHOLDERS EQUITY
Retained Earnings -$144.5M -$126.1M -$108.5M
YoY Change 77.03% 76.58%
Common Stock $3.000K $3.000K $3.000K
YoY Change 0.0% -99.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.9M $147.9M $163.0M
YoY Change
Total Liabilities & Shareholders Equity $143.7M $155.6M $169.4M
YoY Change -25.89% 29.57% 30.93%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$18.37M -$17.58M -$14.50M
YoY Change 80.17% 58.02% 9.21%
Depreciation, Depletion And Amortization $42.00K $44.00K $42.00K
YoY Change 61.54% 76.0% -321.05%
Cash From Operating Activities -$14.74M -$13.55M -$13.73M
YoY Change 35.53% 5.51% 15.11%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K -$14.00K $36.00K
YoY Change -96.92% 250.0% -41.94%
Acquisitions
YoY Change
Other Investing Activities $5.776M -$7.104M -$80.14M
YoY Change 373.6% -7486.36%
Cash From Investing Activities $5.772M -$7.118M -$80.18M
YoY Change -4540.0% 373.27% 14166.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -79.00K 0.000 0.000
YoY Change -100.09% -100.0%
NET CHANGE
Cash From Operating Activities -14.74M -13.55M -13.73M
Cash From Investing Activities 5.772M -7.118M -80.18M
Cash From Financing Activities -79.00K 0.000 0.000
Net Change In Cash -9.042M -20.67M -93.91M
YoY Change -112.18% 37.69% 651.81%
FREE CASH FLOW
Cash From Operating Activities -$14.74M -$13.55M -$13.73M
Capital Expenditures -$4.000K -$14.00K $36.00K
Free Cash Flow -$14.73M -$13.54M -$13.77M
YoY Change 37.13% 5.44% 14.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Assets
Assets
182185000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
RLYB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001739410
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40693
dei Entity Registrant Name
EntityRegistrantName
RALLYBIO CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1083789
dei Entity Address Address Line1
EntityAddressAddressLine1
234 Church Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1020
dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06510
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
859-3820
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32131970
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60753000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175334000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
86615000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6931000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5535000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
154299000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
180869000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
468000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
511000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
613000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
227000
CY2021Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
805000
CY2022Q2 us-gaap Assets
Assets
155607000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
633000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
603000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6495000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5948000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7278000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6551000
CY2022Q2 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
32000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
478000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q2 us-gaap Liabilities
Liabilities
7756000
CY2021Q4 us-gaap Liabilities
Liabilities
6583000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32130970
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32130970
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32129970
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32129970
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
274327000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
269626000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-371000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126108000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94027000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147851000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
175602000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
155607000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182185000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10138000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6818000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30588931
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17786000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15855000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7477000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3712000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14147000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7499000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17615000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
10530000
us-gaap Operating Expenses
OperatingExpenses
31933000
us-gaap Operating Expenses
OperatingExpenses
23354000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17615000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10530000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31933000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23354000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
270000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
13000
us-gaap Interest And Other Income
InterestAndOtherIncome
367000
us-gaap Interest And Other Income
InterestAndOtherIncome
30000
CY2022Q2 us-gaap Interest Expense
InterestExpense
0
CY2021Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
10000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
100000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-142000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
213000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-118000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-129000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
580000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-98000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17245000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10659000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31353000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23452000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-338000
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-468000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-728000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-950000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17583000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11127000
us-gaap Net Income Loss
NetIncomeLoss
-32081000
us-gaap Net Income Loss
NetIncomeLoss
-24402000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1308000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2249000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
787000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
457000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4701000
us-gaap Share Based Compensation
ShareBasedCompensation
4701000
us-gaap Net Income Loss
NetIncomeLoss
-32081000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-371000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
147851000
us-gaap Profit Loss
ProfitLoss
-32081000
us-gaap Profit Loss
ProfitLoss
-24402000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
86000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
48000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
109000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30588931
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22559706
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22559706
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30453913
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30453913
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22309203
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22309203
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-249000
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-371000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-249000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-371000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17832000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11127000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32452000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24402000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
123250000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
539000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11127000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
112662000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
163036000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2647000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17583000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-249000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
147851000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
136003000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1061000
us-gaap Net Income Loss
NetIncomeLoss
-24402000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
112662000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
175602000
us-gaap Share Based Compensation
ShareBasedCompensation
1061000
rlyb Gains Losses On Investment In Joint Venture
GainsLossesOnInvestmentInJointVenture
-728000
rlyb Gains Losses On Investment In Joint Venture
GainsLossesOnInvestmentInJointVenture
-950000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-970000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27285000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24775000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
109096000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
150000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
2000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-87296000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2066000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
663000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-663000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-114581000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-27504000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175334000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140233000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60753000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112729000
rlyb Offering Costs In Accounts Payable And Accrued Expenses
OfferingCostsInAccountsPayableAndAccruedExpenses
0
rlyb Offering Costs In Accounts Payable And Accrued Expenses
OfferingCostsInAccountsPayableAndAccruedExpenses
1762000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
147400000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
700000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2022Q2 rlyb Upfront Payment
UpfrontPayment
3000000.0
CY2022Q2 rlyb Aggregate Development And Regulatory Milestones Payments
AggregateDevelopmentAndRegulatoryMilestonesPayments
43000000.0
CY2022Q2 rlyb Obligation To Payment Upon Maximum Achievement Of Certain Clinical And Commercial Milestones
ObligationToPaymentUponMaximumAchievementOfCertainClinicalAndCommercialMilestones
150000000.0
CY2022Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
100000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
100759000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
371000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
100388000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
100388000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
100388000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
100388000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
86600000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
613000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
478000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
628000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
86000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
200000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
230000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
156000
CY2022Q2 rlyb Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
672000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
628000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
170000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
195000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
230000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
176000
CY2021Q4 rlyb Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
771000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1392995
CY2022Q2 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2847000
CY2021Q4 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1937000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2680000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2955000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
445000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
539000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
523000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
517000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6495000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5948000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32130970
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32129970
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2647000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
539000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4701000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1061000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1357784
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.72
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4027
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.38
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2746752
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
249700
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
22100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2022Q2 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
200000
CY2021Q2 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
1500000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
200000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
2000000.0
rlyb Termination Charges
TerminationCharges
0
CY2021 rlyb Termination Charges
TerminationCharges
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17583000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11127000
us-gaap Net Income Loss
NetIncomeLoss
-32081000
us-gaap Net Income Loss
NetIncomeLoss
-24402000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30588931
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30588931
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22559706
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22559706
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30453913
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30453913
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22309203
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22309203
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09

Files In Submission

Name View Source Status
0000950170-22-015571-index-headers.html Edgar Link pending
0000950170-22-015571-index.html Edgar Link pending
0000950170-22-015571.txt Edgar Link pending
0000950170-22-015571-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img114778283_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlyb-20220630.htm Edgar Link pending
rlyb-20220630.xsd Edgar Link pending
rlyb-ex10_1.htm Edgar Link pending
rlyb-ex31_1.htm Edgar Link pending
rlyb-ex31_2.htm Edgar Link pending
rlyb-ex32_1.htm Edgar Link pending
rlyb-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rlyb-20220630_def.xml Edgar Link unprocessable
rlyb-20220630_lab.xml Edgar Link unprocessable
rlyb-20220630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
rlyb-20220630_cal.xml Edgar Link unprocessable
rlyb-20220630_pre.xml Edgar Link unprocessable